NXLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

Nexalin Technology, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$2.36+0.01 (+0.43%)

Close on Oct 19, 2026

Market cap: $49.90M
P/E (TTM): –
Dividend yield: –

Nexalin Technology, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	0.30	0.17	0.11	1.32	0.14	–
Cost of Revenue	0.06	0.04	0.03	0.36	0.02	–
Gross Profit	0.24	0.13	0.09	0.96	0.12	–
Research & Development	1.08	1.19	1.92	0.51	0.14	1.50
Selling, General & Admin	4.40	4.23	1.90	1.49	5.22	–
General & Administrative	3.13	2.55	2.37	–	–	–
Advertising Expenses	–	–	0.01	0.02	0.04	–
Operating Expenses	8.63	7.89	5.78	2.79	6.14	–
Operating Income	-8.39	-7.75	-5.70	-1.83	-6.02	–
Interest Expense	-0.01	0.00	0.04	0.06	0.08	–
Other Non-Operating Income	0.17	0.14	1.05	0.14	-0.06	–
Asset Impairment Charges	0	0	–	–	–	–
Gain (Loss) on Investments	0.13	0.13	0.23	–	–	–
Pretax Income	-8.22	-7.61	-4.65	–	–	–
Net Income incl. Noncontrolling Interests	-8.22	-7.61	-4.65	–	–	–
Net Income	-8.22	-7.61	-4.65	-1.70	-6.08	–
EPS (Basic)(per share)	-0.50	-0.83	-0.63	-0.30	–	–
EPS (Diluted)(per share)	-0.50	-0.83	-0.63	-0.30	–	–
Shares Outstanding (Basic, Weighted)(shares)	16	9.22	7.36	5.57	–	–
Shares Outstanding (Diluted, Weighted)(shares)	16	9.22	7.36	5.57	–	–
Net Interest Income	-0.01	0.00	0.04	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 86.2%
Operating margin: -4202.5%
Net margin: -4139.4%
Return on equity, FY2025: -221.5%

Financial strength

Current ratio: 1.25
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 67.7%

Valuation

P/E ratio: –
Price to sales: 229.78
Price to book: 32.84
Dividend yield: –